Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$163.85 USD
+3.13 (1.95%)
Updated Jun 24, 2024 04:00 PM ET
After-Market: $163.87 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$163.85 USD
+3.13 (1.95%)
Updated Jun 24, 2024 04:00 PM ET
After-Market: $163.87 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Zacks News
Company News For Dec 24, 2019
by Zacks Equity Research
Companies in the news are: ACB, APA, ITCI, SRPT
Sarepta Signs Gene Therapy Agreement With Roche for $1.15B
by Zacks Equity Research
Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion. Sarepta is also eligible to receive $1.7 billion in milestone payments.
Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up
by Zacks Equity Research
Sarepta (SRPT) exon-53 skipping DMD drug, Vyondys 53, gets approval in the United States following a CRL in August.
Why Is Sarepta Therapeutics (SRPT) Up 17.2% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
by Ekta Bagri
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal
by Zacks Equity Research
Sarepta (SRPT) expands its footing in the gene therapy field and signs a deal with StrideBio to develop up to eight new treatments.
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -26.87% and 1.61%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News For Oct 7, 2019
by Zacks Equity Research
Companies in the news are: COST, BP, HPQ and SRPT
Why Is Sarepta Therapeutics (SRPT) Down 33.1% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sarepta Therapeutics (SRPT) stock based on the movements in the options market lately.
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Company News For Aug 21, 2019
by Zacks Equity Research
Companies in the news are: KSS, MDT, BIDU and SRPT
Sarepta Stock Falls as FDA Denies Approval to Golodirsen
by Zacks Equity Research
The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.
Solid Biosciences Surges on DMD Gene Therapy Study Amendments
by Zacks Equity Research
Solid Biosciences (SLDB) amends its phase I/II gene therapy study protocol to expedite the development of its lead candidate, SGT-001, as potential treatment for DMD.
Sarepta Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Sarepta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year. The company plans expansion of gene therapy program into other indications including multiple sclerosis.
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -246.30% and 3.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Has Sarepta Therapeutics (SRPT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (SRPT) Outperforming Other Medical Stocks This Year?
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive second-quarter sales.